Independent validation of LIPA as a molecular target in TNBC
Dallas, TX. October 2, 2023: Etira is pleased to note the independent validation of LIPA as a molecular target in TNBC in a preprint in biorxiv from Dr. Esser’s group in Dusseldorf, Germany.
The authors conclude that LIPA-activity is a novel pharmacological target in TNBC therapy and argue for the implementation of LIPA inhibitors into personalized treatment in the future. These findings support our approach with drugs like ERX-41 and ERX-315 that target LIPA. Our phase I clinical trial with ERX-315 is scheduled to begin in Q2 2024.
